Gerresheimer's Survival Hinges on Bank Talks and Asset Fire Sale

German pharma packaging giant Gerresheimer fights for survival after breaching loan covenants due to €35M accounting scandal, facing BaFin probe and urgent asset sales.

The German pharmaceutical packaging group Gerresheimer is fighting for its financial life, with its survival now dependent on the goodwill of its lenders. The company has breached its loan covenants after failing to publish audited financial statements, plunging it into technical default. Management is in urgent talks with creditors to secure waivers and prevent a termination of its credit facilities, a move that would be catastrophic.

At the heart of the crisis are improper accounting practices. Auditors identified €35 million in premature 2024 revenues from inadmissible "bill-and-hold" agreements that violated IFRS standards. This discovery has frozen the entire financial reporting cycle. The absence of a certified annual report for 2025 means the company cannot hold its annual general meeting and is violating contractual reporting obligations to its banks.

Regulatory scrutiny is intensifying on multiple fronts. Germany's financial watchdog, BaFin, has expanded its investigation to cover the period from December 2024 to May 2025. Its probe now includes questionable leasing liabilities worth €65.5 million and capitalized development costs. In a separate action, the audit oversight body APAS has initiated professional misconduct proceedings against auditor KPMG. The firm is accused of issuing an unqualified audit opinion on the faulty 2024 accounts shortly after taking over the mandate from Deloitte.

To generate urgently needed liquidity and stabilize its balance sheet, Gerresheimer's board is pulling the emergency brake. It has mandated Morgan Stanley to sell its Centor segment, which specializes in medication packaging, with the divestment targeted for this year. Concurrently, the company is shutting down its Moulded Glass plant in Chicago Heights, shifting production to India and Italy.

These drastic measures come with a heavy financial cost. The group anticipates non-cash impairment charges of up to €240 million, primarily related to the Chicago facility and technology projects at its subsidiary Sensile Medical AG.

The uncertainty has devastated the company's share price. The stock, trading at €17.09, has plummeted nearly 68% over the past twelve months. It has also been ejected from the SDAX index, triggering forced selling by index-tracking funds and adding further downward pressure on the equity. Since the start of the year, the share price has fallen approximately 38%.

While management has issued a revenue forecast of up to €2.4 billion for 2026 with an adjusted EBITDA margin around 18%, this outlook is currently viewed as almost meaningless. It is explicitly conditional on successful credit negotiations and a positive outcome from the BaFin investigation. All parties are now focused on a hard deadline in June 2026, by which time a certified annual report for 2025 must be delivered. Until then, the fate of Gerresheimer's current corporate structure rests entirely in the hands of its bankers.